Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-15

Study Completion Date

2019-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Soil-transmitted helminths (STHs) are a group of parasitic worms that infect millions of children in sub-tropical and tropical countries, resulting in malnutrition, growth stunting, intellectual retardation and cognitive deficits. To control the morbidity due to these worms, school-based deworming programs are implemented, in which anthelminthic drugs are administered to children without prior diagnosis. The continued fight against these worms is aided by the London declaration on neglected tropical diseases, which helps sustain and expand global drug donation program, resulting in an unprecedented growth of deworming programs. However, the high degree of drug pressure makes deworming programs vulnerable to the development of anthelmintic resistance because they only rely on one drug with sometimes suboptimal efficacy and there is no availability of alternative drugs. Moreover, at present, there is no surveillance system to monitor the emergence and spread of anthelmintic resistance. It remains unclear to what extent the efficacy of drugs may have dropped and whether anthelmintic resistance is already present.

This project aims to strengthen the monitoring and surveillance of drug efficacy and anthelmintic resistance in STH programs. As such, it will support deworming programs in their quest to eliminate STHs as a public health problem.

The specific objectives of the first work package are to validate diagnostic tools to monitor drug efficacy and the spread of anthelmintic resistance, and to validate molecular markers for benzimidazole resistance.

This study will be conducted at four different sites (Ethiopia, Tanzania, Lao PDR and Brazil) and will focus on school-aged children (age 5-14). At baseline subjects will be asked to provide a recent stool sample which will be processed using 3 different microscopic techniques (KK, Mini-Flotac and FECPAKG2). All children will be treated with a single-oral dose of albendazole (ALB) 400 mg and 14-21 days after treatment, a second stool sample will be collected from all children to again determine the fecal egg counts. At each sampling, stool is stored in preservative. Stored stool will be shipped to Belgium for DNA extraction and quantitative PCR (qPCR) analysis. A subset of the samples will be analysed by pyrosequencing to evaluate the single nucleotide polymorphisms in the b-tubulin gene. Pooling of the stored samples will also be performed to compare with the values obtained from analysing individual samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

NCT01379326

Ascaris Lumbricoides Ascaris Suum Trichuris Trichiura +5 more

COMPLETED PHASE4

Assessment of Drug Efficacy of Local Albendazole

NCT02420574

Helminthiasis

COMPLETED NA

Relative Efficacy of Two Regimens of Ante-helminthic Treatment

NCT00367627

Helminthiasis

COMPLETED NA

A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children

NCT01087099

Infections With Soil-Transmitted Helminths (STH)

COMPLETED PHASE4

Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya

NCT02397772

Helminthiasis Nematode Infection Disease Transmission, Infectious

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background Soil-transmitted helminths (STHs) are a group of parasitic worms that infect millions of children in sub-tropical and tropical countries, resulting in malnutrition, growth stunting, intellectual retardation and cognitive deficits. To control the morbidity due to these worms, school-based deworming programs are implemented, in which anthelminthic drugs are administered to children without prior diagnosis. The continued fight against these worms is aided by the London Declaration on Neglected Tropical Diseases, which helps sustain and expand global drug donation program, resulting in an unprecedented growth of deworming programs. to illustrate, in the last four years the coverage of mass drug administration (MDA) has doubled from 30 to 60%, and ongoing global efforts are made to ultimately reach the milestone of 75% by 2020.

Threats While the laudable long-term aim is to eliminate STHs as a public health problem by 2020, and to eventually declare targeted geographical areas free from infections, this high degree of drug pressure makes deworming programs vulnerable to the development of anthelmintic resistance because the programs only rely on one drug with sometimes suboptimal efficacy and there is no availability of alternative drugs.

Challenges

At present, there is no surveillance system to monitor the emergence and spread of anthelmintic resistance. It remains unclear to what extent the efficacy of drugs may have dropped and whether anthelmintic resistance is already present. However, developing such a system is not straightforward. Deworming programs typically operate in resource-constrained settings, and program managers require some flexibility to minimize both financial and technical resources, while ensuring a reliable assessment of the drug efficacy. The most important obstacles to globally monitor patterns of changing drug efficacy and spread of anthelmintic resistance are the following:

* the shortage of diagnostic laboratories with experienced staff to perform the surveys and analyze and report the obtained data
* the absence of a quality assurance system that guarantees auditable results
* the lack of guidance in designing surveys as the programs progresses
* the lack of data supporting the validity of molecular markers to detect anthelmintic resistance in human STHs
* the lack of sensitive and point-of-care tools that allow the detection of low frequencies of anthelmintic resistance Main objective This project aims to strengthen the monitoring and surveillance of drug efficacy and anthelmintic resistance in STH programs. As such, it will support deworming programs in their quest to eliminate STHs as a public health problem by 2020.

The specific objectives of the first part of the project are to validate diagnostic tools to monitor drug efficacy and the spread of anthelmintic resistance, and to validate molecular markers for benzimidazole resistance.

Study protocol This study will conducted at four different sites at Africa (Ethiopia and Tanzania), Asia (Lao PDR) and Latin-America (Brazil). The selection of these sites is based on their experience in assessing drug efficacy and evaluating the performance of diagnostic tools, the availability of well-equipped diagnostic facilities and skilled personnel, and their national MDA history.

The study will focus on school-aged children (age of 5 to 14 years). At baseline subjects will be asked to provide a recent (within 4 hours) stool sample of at least 9 grams. All stool samples will be processed using the FECPAKG2, a duplicate Kato-Katz thick smear (the most commonly applied fecal egg count (FEC) technique) and Mini-Flotac (a novel technique that has a sensitivity at least equal to that of Kato-Katz). All children providing a stool sample will be provided a single-oral dose of ALB 400 mg under supervision. Fourteen to 21 days after treatment, a second stool sample will be collected from all the children that proved positive for any STH species at baseline to determine the FECs.

At each sampling, 2x 1 gram of stool is stored in preservative for downstream molecular analysis. Stored stool will be shipped to Belgium for DNA extraction and qPCR analysis. A subset of the samples will be analysed by Pyrosequencing to evaluate the single nucleotide polymorphisms in the b-tubulin gene.

Pooling of the stored samples will also be performed to compare with the values obtained from analysing individual samples.

Data handling Data will first be recorded on specific study record forms. These results will then be entered into the custom designed Excel-files by two different data entry clerks to minimize errors in data due to incorrect data entry.

Study management Studies in the different sites will be organized and supported out of Ghent University. The project team members will travel to each individual trial site to train local personnel in the different coprological techniques and to get them acquainted with the trial protocol and documents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Soil-transmitted Helminth Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects

All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.

Group Type EXPERIMENTAL

Albendazole Pill 400mg (GSK)

Intervention Type DRUG

One single dose of 400mg Albendazole is provided at baseline.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albendazole Pill 400mg (GSK)

One single dose of 400mg Albendazole is provided at baseline.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Albendazole 400mg form GlaxoSmithKline (Batch Nr: 335726)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject, male or female, is 5-14 years of age
* Subject is otherwise in an healthy condition (medical history and physical examination)
* Parent(s)/guardians of subjects (or their legally-accepted representatives) signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study.
* Subject of ≥6 years has assented (agreed) to participate in the study.
* Subject of ≥12 has signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
* The subject swallowed the entire drug (ALB 400 mg) under supervision
* Subject provides a stool sample of at least 9 grams

Exclusion Criteria

* Subject has active diarrhea (defined as the passage of 3 or more loose or liquid stools per day) at baseline or follow-up
* Subject has any acute medical condition or is experiencing a severe concurrent medical condition
* Subject has a known hypersensitivity to benzimidazole drugs
* Subject has received an anthelminthic treatment within 90 of the start of the treatment.
* Subject vomited within 4 hours after drug administration
* Subject is unable to provide a stool sample at follow-up

Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes